Chromatin Regulation / Acetylation
JARID1C (D29B9) Rabbit mAb
|
イイネ!(0)
|
|
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #5361S | 100 μL | 46,000 | |
|
JARID1C抗体製品一覧
5361 の推奨プロトコール
最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注:各製品に最適化されたプロトコールをリンクしています。
| | |
-
5361:
-
Immunoprecipitation
Western Blotting
| 用途(希釈倍率) | |
| ウェスタンブロッティング (1:1,000)、免疫沈降 (1:50) |
| 特異性・感度 | |
| 内在性レベルのJARID1C タンパク質を検出します。JARID1A、JARID1B、JARID1D などの他のJARID タンパク質とは交差しません。 |
| 使用抗原 | |
| ヒトのJARID1C タンパク質のLeu830 周辺領域 (合成ペプチド) |
| ※括弧付きの動物種は、配列が100%相同であるため反応すると推定されます。 |
Western Blotting

Western blot analysis of extracts from NCCIT and F9 cell lines using JARID1C (D29B9) Rabbit mAb.
The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX) and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is over-expressed in many breast cancers and may act by repressing multiple tumor suppressor genes including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is largely uncharacterized.
-
Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop , 1-27.
-
Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
-
Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
-
Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
-
Christensen, J. et al. (2007) Cell 128, 1063-76.
-
Yamane, K. et al. (2007) Mol Cell 25, 801-12.
-
Tahiliani, M. et al. (2007) Nature 447, 601-5.
-
Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
-
van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
-
Secombe, J. et al. (2007) Genes Dev 21, 537-51.
-
Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
-
Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
-
Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
-
Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
-
Tzschach, A. et al. (2006) Hum Mutat 27, 389.
-
Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.